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Current Biology 28, R1171-R1189, October 22, 2018 © 2018 Elsevier Ltd. maps of the SC and classic FEF are different, and only few FEF cells encode ipsilateral saccades [8] (with an unknown motor map). Possible further support for this argument is that SE had spared FEFs and weak probe effects.
A brief current pulse to the superfi cial layer of the rat SC produces a prolonged (~300 ms) burst of excitatory postsynaptic current in intermediate layer cells [10] . An additional input to the deeper layers could trigger a saccade. By extension, a visual stimulus in the blind hemifi eld of our patients could not, on its own, trigger a goal-directed saccade, presumably because motor activity in the intermediate layers of the ipsilesional SC (SCi) is absent. Thus, we hypothesize, mostly for DR, that probe-evoked activity in retino-tectal afferents to the SCi's superfi cial layers descended to intermediate layers and enhanced weak motor preparatory activity for contralesional anti-saccades, itself due to a crossed descending motor signal from contralesional FEF-to-SCi [4, 8] . The many and varied residual abilities among blindsight patients suggest that blindsight relies on more than one residual pathway. Here we provide evidence indicating that the mammalian homologue of the primitive reptilian retino-tecto-reticular pathway is remarkably functional in humans, thus permitting a form of 'action' blindsight [1] . Research using NHPs, although it is facing serious challenges, continues to complement studies in human volunteers and patients, and will continue to be needed as the burdens of mental health problems and neurodegenerative diseases increase. At the same time, research into the 3Rs is helping to ameliorate the harms experienced by NHPs in experimental procedures, allowing the effective combination of optimal welfare conditions for the NHPs and high quality research. We write as a group of UK scientists committed to neuroscience research in NHPs at a critical point in the debate over their use in research. Our commitment stems from the notable advances that this research has already achieved, and because of our awareness that the monkey represents the best available model for our understanding of the human brain. Last year, the EU SCHEER report [1] highlighted key research areas where NHPs were still needed. These included testing of new drugs, infectious diseases (including Ebola, Zika and TB), and neuroscience. The need to alleviate the modern burdens of human neurodegenerative diseases and mental health disorders represents one of the most powerful arguments for sustaining primate research. This research now engages modern molecular, electrophysiological, behavioural and
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We emphasise that NHP studies, using invasive methods, complement those in human volunteers and patients, using non-invasive methods such as brain imaging and computational modelling. For example, the Brain Prize in 2017 was awarded to three scientists in the UK who, respectively, discovered the neuronal mechanism of reward in monkeys, modelled this reward mechanism, and tested these models in human volunteers using fMRI [2] . Recent analysis shows that scientists who use NHPs in their research are also very active in using non-animal approaches to address current problems in basic and translational neuroscience [3] . NHP scientists also contribute to advances in welfare and the 3Rs [3] .
Similarly, close interaction between human and monkey studies was also vital to the development of the parkinsonian model in the macaque which led to the discovery that deep brain stimulation of a tiny brain structure, the subthalamic nucleus, was an effective therapy for the motor disorders associated with Parkinson's disease, research that was recognised by the Lasker Award in 2014 [4] . Over 250,000 Parkinson patients worldwide have since benefi ted from this treatment. Recent developments that have come directly from monkey research include the use of brain-machine interfaces for restoring movement to paralysed patients, new therapies for stroke patients with poor hand function, new strategies to harness brain plasticity to compensate for perceptual and cognitive impairment, and a better understanding of symptoms underlying psychiatric disorders as well as cognitive functioning in the healthy brain.
UK and EU animal research legislation requires a 'harm-benefi t' analysis to determine whether the harms involved in the research are justifi ed by advances in fundamental science or medical benefi ts that might result from the study. Therefore, in addition to assessing the benefi ts of NHP research, there has been an increased focus on reducing harms and understanding the overall level of severity experienced by research animals. This is of particular signifi cance for NHPs in long-term neuroscience studies involving complex behavioural tasks.
Government regulators in the UK, and in some other EU countries, prospectively assess all such research as 'severe' because of the potential to cause severe harm. Critically, accumulating evidence shows that the lifetime experience of a great majority of the monkeys used in academic research in the UK is not severe, but is actually 'moderate'. Starting in 2013, annual retrospective reviews of the actual severity experienced by each monkey in neuroscience research procedures has revealed that only 1% of the 366 monkeys used (New World marmosets and Old World macaques) actually experienced severe harms (as defi ned by the EU Directive 2013/63/), while most (66%) experienced moderate harms, or less (26% 'mild' and 7% 'non-recovery'). These results are consistent with the broader set of United Kingdom Home Offi ce statistics for basic research using NHPs over the same period (3% of severe procedures for the years 2013-2016). They also confi rm the moderate level of harms that was fi rst reported by the Home Offi ce Pickard Report in 2013 [5] . This key distinction between the potential to cause severe harm and the actual level of severity is crucial but is often lost or misunderstood in discussions amongst the general public.
We are seriously concerned about calls to UK and other EU government regulators for a ban on all research involving NHPs, as well as in many other species, which has a prospective rating of severe. Such a ban would prevent diseaserelated medical and neuroscience research, damaging both fundamental and translational science. We have identifi ed two serious consequences that such a ban would cause to NHP neuroscientifi c research; many more exist and will develop, impacting the wider scientifi c community, the welfare of non-human species, and human health.
First, it would ban most of the basic, fundamental neuroscience research, essential for understanding complex cognition and other processes that occur in the primate brain. We stress that the ban would result from the current situation in which most NHP neuroscience research is currently prospectively banded severe by government regulators, although as pointed out above, the great majority of primates used actually experience moderate harms or less.
Second, it would ban any present (or future) study in which a disease model is created in a monkey, indeed necessarily causing severe harms that refl ect the impact of the brain disorder (e.g. Parkinson's) in humans. But limited use of such models is still essential to help fi nd effective treatments for a whole range of neurodegenerative and neuropsychiatric conditions that affect millions of humans.
We believe that in the coming period some increase in NHP studies in carefully targeted areas of neuroscience will still be needed. To ban useful primate disease models would be an extremely dangerous step to take, given the urgent need to fi nd treatments for people suffering from these conditions.
